Biopharma Co Vyome gets Rs 154 crore from investors

New Delhi: Vyome Therapeutics, a biopharmaceutical firm focused on developing dermatology products, has raised $22 million (about Rs 154 crore) in a fresh round of funding led by Mumbai based venture growth fund Iron Pillar to expand its team and further invest in research and development.

Existing investors Perceptive Advisors, Romulus Capital and Kalaari Capital also participated in this round. Part of the funds are being used for a secondary transaction, the company said without elaborating. Prior to this round, the company had raised about $30 million from Perceptive Advisors, Romulus Capital, Kalaari Capital, Sabre Partners India, Aarin Capital and Navam Capital.

Dermatological conditions are among the most common types of disorders globally and a majority of the market share is held by large pharmaceutical firms with established product lines. However, with the emergence of a number of startups which have proven clinical and commercial success along with d eep understanding of many dermatological conditions, there is a renewed investor interest in disruptive companies in this segment.

  • Related Posts

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid